When it comes to short-term investing or trading, they say "the trend is your friend." And there's no denying that this is the most profitable strategy. But making sure of the sustainability of a trend to profit from it is easier said than done.Often, the direction of a stock's price movement reverses quickly after taking a position in it, making investors incur a short-term capital loss. So, it's important to ensure that there are enough factors -- such as sound fundamentals, positive earnings estimate rev ...

| --- | |-------| | | | | | | | | | | | | | | | | | | Rob Fried Chief Executive Officer Ozan Pamir Chief Financial Officer Andrew Shao SVP Scientific & Regulatory Affairs Nasdaq: CDXC | October 31, 2024 SAFE HARBOR STATEMENT 2 This presentation and other written or oral statements made from time to time by representatives of ChromaDex contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as am ...

ChromaDex (CDXC) came out with quarterly earnings of $0.02 per share, beating the Zacks Consensus Estimate of $0.01 per share. This compares to loss of $0.01 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 100%. A quarter ago, it was expected that this natural products company would post a loss of $0.03 per share when it actually produced break-even earnings, delivering a surprise of 100%.Over the last four quarters, the compa ...

ChromaDex Corporation Reports Third Quarter 2024 Financial Results Total net sales of $25.6 million, up $6.1 million or 31% year-over-year, gross margin of 63.5% and record net income and Adjusted EBITDA of $1.9 million and $2.9 million, respectively, for the three months ended September 30, 2024. LOS ANGELES, CA - October 31, 2024 - ChromaDex Corp. (NASDAQ:CDXC) today announced financial results for the third quarter of 2024. Third Quarter 2024 Financial and Recent Operational Highlights • Total net sales ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 Commission File Number: 001-37752 CHROMADEX CORPORATION (Exact Name of Registrant as Specified in its Charter) | --- | --- | --- | |----------------------------------------------------------------------------------|----------------------------|---------------------------------------------- ...

We expect investors to focus on the sales performance of ChromaDex Corp.'s (CDXC) marketed product, Niagen, and updates on the pipeline when it reports third-quarter 2024 results on Oct. 31, after market close. The Zacks Consensus Estimate for the to-be-reported quarter's revenues is pegged at $23.70 million, while the same for earnings is pinned at 1 cent per share. Stay up-to-date with all quarterly releases: See Zacks Earnings Calendar. Let's see how things might have shaped up for the quarter to be repo ...

For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Is ChromaDex (CDXC) one of those stocks right now? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question. ChromaDex is a member of our Medical group, which includes 1025 different companies and currently sits at #2 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sec ...

The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. ChromaDex (CDXC) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? Let's take a closer look at the stock's year-to-date performance to find out. ChromaDex is one of 1015 individual stocks in the Medical sector. Collectively, these companies sit at #6 in the Zacks Sector Rank. The Zacks Se ...

Financial Data and Key Metrics - The company reported $22.7 million in revenue for Q2 2024, a 12% year-over-year increase, with a near breakeven net income of a $15,000 net loss [6] - Adjusted EBITDA was $1.6 million, marking the fifth consecutive quarter of positive adjusted EBITDA [6] - The company ended the quarter with $27.9 million in cash and no debt [7] - Gross margins remained strong at 60.2%, slightly down from 60.8% in Q2 2023 [26] - Operating loss improved to $0.3 million from $2.3 million in Q2 2023, driven by higher net sales and lower operating expenses [28] Business Line Data and Key Metrics - E-commerce revenue remained stable at $13 million, continuing to be the largest and most consistent revenue source [16] - TRU Niagen sales increased by 10%, while combined Watsons and other B2B sales grew by 44% [25] - Niagen Plus product line was launched, featuring pharmaceutical-grade Niagen in IV and injectable forms, targeting a global market valued at over $2 billion [8][9] - The company introduced the Niagen Plus NAD test kit, exclusively for healthcare practitioners to measure NAD levels [10] Market Data and Key Metrics - The NAD IV market in the U.S. is estimated to be between $100 million and $150 million, with the company targeting more than 50% market share [46][47] - The company is expanding its presence in China, where NMN sales have dropped dramatically, but TRU Niagen has not yet seen significant growth [59][60] Company Strategy and Industry Competition - The company is focusing on innovation, with the launch of Niagen Plus and the development of new NAD precursors [10][27] - ChromaDex is committed to maintaining fiscal discipline while supporting upcoming launches and key initiatives [6] - The company is addressing competition from brands promoting NAD-boosting products that do not meet their claims, emphasizing Niagen's superior quality [19] Management Commentary on Operating Environment and Future Outlook - Management highlighted the potential of Niagen IV to expand the NAD IV market due to its superior tolerability and faster infusion times [8][42] - The company anticipates 10% to 15% year-over-year growth for 2024, driven by e-commerce, partnerships, and the launch of Niagen IV [29] - Management expressed optimism about the potential therapeutic benefits of NR in treating Parkinson's disease and Ataxia Telangiectasia [12][13][83] Other Important Information - The company received orphan drug designation from the U.S. FDA for NR as a candidate for treating Ataxia Telangiectasia [12] - A new patent was granted in Europe for the use of nicotinamide riboside in the treatment of Parkinson's disease [13] - The company is collaborating with Nestle Health Science to integrate Niagen into their brands, including the launch of NR Longevity [21] Q&A Session Summary Question: Adoption of Niagen Plus and Market Share Expectations - The company expects to capture more than 50% market share due to Niagen's superior product quality, but supply chain challenges have delayed the rollout [34][39] - Initial shipments of Niagen IV are limited, with a larger batch expected in October [39] Question: Pricing and Gross Margin Impact of Niagen IV - Niagen IV is priced slightly higher than existing NAD IV products, with margins higher than the company's corporate margin, expected to positively impact gross margins [57] Question: Timing and Impact of Niagen Plus Rollout - The delay in Niagen Plus rollout is not expected to impact the company's mid-2025 expectations for revenue or spending [64] Question: Market Expansion Potential for Niagen IV - The existing NAD IV market has not been growing, but the company believes Niagen IV could expand the market due to its superior product experience [66][68] Question: Regulatory Process for Ataxia Telangiectasia (AT) and Cockayne Syndrome - The regulatory process for AT is further along than Cockayne Syndrome, with human clinical studies already conducted for AT [48][49] Question: B2B Sales Growth and Order Patterns - B2B sales growth of 44% is partly driven by a customer aggressively marketing a combination product featuring Niagen on Amazon [52][53] Question: Green Hat Approval in China - The company has not seen any changes in the outlook for Green Hat approval in China, despite the decline in NMN sales [75] Question: Launch Timeline for Injectable Products - Injectable products for clinics are expected to be available in 2-3 months, with at-home injectable products potentially launching by the end of 2024 or early 2025 [78] Question: Addressable Market for Parkinson's Disease - If the Phase III NO-PARK study yields positive results, the company sees a significant opportunity to market Niagen as a dietary supplement to Parkinson's patients, with a global addressable market of approximately 10 million patients [83][85]

| --- | --- | |-----------------------|-------| | | | | ChromaDex | | | | | | | | | Earnings Presentation | | | Second Quarter 2024 | | Rob Fried Chief Executive Officer James Lee Interim Chief Financial Officer Andrew Shao SVP Scientific & Regulatory Affairs Nasdaq: CDXC | August 7, 2024 SAFE HARBOR STATEMENT 2 This presentation and other written or oral statements made from time to time by representatives of ChromaDex contain "forward-looking statements" within the meaning of Section 27A of the Securities ...